Evidence map›Paper›PMID 38784816›Full record

ArticleFrontiers in microbiology2024

Persistence and risk factors of occult hepatitis B virus infections among antiretroviral therapy-naïve people living with HIV in Botswana.

Motswedi Anderson, Bonolo B Phinius, Basetsana K Phakedi, Mbatshi Mudanga, Lynnette N Bhebhe, Girlie N Tlhabano, Patience Motshosi, Tsholofelo Ratsoma, Kabo Baruti, Gorata Mpebe and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. The miRNomics of antiretroviral therapy-induced obesity.Functional & integrative genomics · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Motswedi AndersonResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Bonolo B PhiniusResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Basetsana K PhakediResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Mbatshi MudangaBotswana - University of Maryland School of Medicine Health Initiative, Gaborone, Botswana.
Lynnette N BhebheResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Girlie N TlhabanoResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Patience MotshosiResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Tsholofelo RatsomaResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Kabo BarutiResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Gorata MpebeResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Wonderful T ChogaResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Richard MarlinkResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Dieter GlebeInstitute of Medical Virology, National Reference Centre for Hepatitis B Viruses and Hepatitis D Viruses, Justus Liebig University of Giessen, Giessen, Germany.
Jason T BlackardDivision of Digestive Diseases, University of Cincinnati College of Medicine, Cincinnati, OH, United States.
Sikhulile MoyoResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.
Anna KramvisHepatitis Virus Diversity Research Unit, Department of Internal Medicine, School of Clinical Medicine, University of the Witwatersrand, Johannesburg, South Africa.
Simani GaseitsiweResearch Laboratory, Botswana Harvard Health Partnership, Gaborone, Botswana.

Funding

H3ABioNet: a sustainable African Bioinformatics Network for H3AfricaU41HG006941 · NHGRI · UNIVERSITY OF CAPE TOWN · PI MULDER, NICOLA · 2012 to 2017
$14.8M
Training in HIV Genomics, Treatment, and Cure Research in BotswanaD43TW009610 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI SHAHIN LOCKMAN, Joseph Moeketsi Makhema · 2013 to 2026
$4.4M
Mentoring in Patient-Oriented HIV Research in the Era of Universal ARTK24AI131928 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI SHAHIN LOCKMAN · 2017 to 2026
$1.9M
Expansion of research and mentoring to improve birth outcomes and treatment outcomes among HIV-affected children in BotswanaK24AI131924 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Roger L Shapiro · 2018 to 2026
$1.6M
Viral Diversity an Innovative Biomarker for Refining Estimates of HIV IncidenceK43TW012350 · FIC · THE BOTSWANA HARVARD HEALTH PARTNERSHIP · PI Sikhulile Moyo · 2022 to 2026
$682k
Bill & Melinda Gates Foundation INV-033558FIC NIH HHS D43 TW009610FIC NIH HHS K43 TW012350NHGRI NIH HHS U41 HG006941NIAID NIH HHS K24 AI131924NIAID NIH HHS K24 AI131928Wellcome Trust
6 · The paper itself

Abstract

Aim: This study aimed to determine the kinetics of occult hepatitis B virus infections (OBI) among people with HIV (PWH). Methods: The study used archived plasma samples from longitudinal HIV natural history studies. We identified new OBI cases and assessed risk factors for OBI using Cox proportional hazards regression analysis. Results: At baseline, 8 of 382 [(2.1%) (95% CI: 1.06-4.1)] samples tested positive for hepatitis B surface antigen (HBsAg Conclusion: There was a high rate of newly identified OBI among young PWH in Botswana, especially in men and in participants with lower CD4

Indexed as

HBVhepatitis B virusHIV/HBV, hepatitis B surface antigen (HBsAg) negativeincidenceOBIoccult hepatitis B

Identifiers

PMID38784816
PMCPMC11112038

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.